KRAS and cancer: In the adjusted analysis, multivariate Cox proportional hazards models confirmed significantly longer OS (HR = 0.55, P = .0008) and PFS with first-line systemic therapies (HR = 0.58, P = .0061) in patients with cancers harboring KRAS G12R vs. non-G12R mutations (Table 2).